Literature DB >> 19734449

Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities.

Anja Mottok1, Christoph Renné, Marc Seifert, Elsie Oppermann, Wolf Bechstein, Martin-Leo Hansmann, Ralf Küppers, Andreas Bräuninger.   

Abstract

STATs are constitutively activated in several malignancies. In primary mediastinal large B-cell lymphoma and Hodgkin lymphoma (HL), inactivating mutations in SOCS1, an inhibitor of JAK/STAT signaling, contribute to deregulated STAT activity. Based on indications that the SOCS1 mutations are caused by the B cell-specific somatic hypermutation (SHM) process, we analyzed B-cell non-HL and normal B cells for mutations in SOCS1. One-fourth of diffuse large B-cell lymphoma and follicular lymphomas carried SOCS1 mutations, which were preferentially targeted to SHM hotspot motifs and frequently obviously inactivating. Rare mutations were observed in Burkitt lymphoma, plasmacytoma, and mantle cell lymphoma but not in tumors of a non-B-cell origin. Mutations in single-sorted germinal center B cells were infrequent relative to other genes mutated as byproducts of normal SHM, indicating that SOCS1 inactivation in primary mediastinal large B-cell lymphoma, HL, diffuse large B-cell lymphoma, and follicular lymphoma is frequently the result of aberrant SHM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734449     DOI: 10.1182/blood-2009-06-225839

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  MicroRNA 155 control of p53 activity is context dependent and mediated by Aicda and Socs1.

Authors:  Hakim Bouamar; Daifeng Jiang; Long Wang; An-Ping Lin; Manoela Ortega; Ricardo C T Aguiar
Journal:  Mol Cell Biol       Date:  2015-02-02       Impact factor: 4.272

Review 2.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

3.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

4.  The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.

Authors:  I Vater; M Montesinos-Rongen; M Schlesner; A Haake; F Purschke; R Sprute; N Mettenmeyer; I Nazzal; I Nagel; J Gutwein; J Richter; I Buchhalter; R B Russell; O D Wiestler; R Eils; M Deckert; R Siebert
Journal:  Leukemia       Date:  2014-09-05       Impact factor: 11.528

5.  Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2018-08-21       Impact factor: 4.064

Review 6.  From genetics to the clinic: a translational perspective on follicular lymphoma.

Authors:  Sarah Huet; Pierre Sujobert; Gilles Salles
Journal:  Nat Rev Cancer       Date:  2018-02-09       Impact factor: 60.716

7.  AID-associated DNA repair pathways regulate malignant transformation in a murine model of BCL6-driven diffuse large B-cell lymphoma.

Authors:  Xiwen Gu; Carmen J Booth; Zongzhi Liu; Matthew P Strout
Journal:  Blood       Date:  2015-09-18       Impact factor: 22.113

Review 8.  [Grayzone lymphoma. Clinical relevance].

Authors:  S Hartmann; M L Hansmann
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

9.  Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.

Authors:  Dominik Nann; Joan Enric Ramis-Zaldivar; Inga Müller; Blanca Gonzalez-Farre; Janine Schmidt; Caoimhe Egan; Julia Salmeron-Villalobos; Guillem Clot; Sven Mattern; Franziska Otto; Barbara Mankel; Dolors Colomer; Olga Balagué; Vanessa Szablewski; Carmen Lome-Maldonado; Lorenzo Leoncini; Stefan Dojcinov; Andreas Chott; Christiane Copie-Bergman; Irina Bonzheim; Falko Fend; Elaine S Jaffe; Elias Campo; Itziar Salaverria; Leticia Quintanilla-Martinez
Journal:  Blood Adv       Date:  2020-11-24

10.  New developments in the pathology of malignant lymphoma: a review of the literature published from August to November 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-12-17       Impact factor: 0.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.